|
Market Cap (6-Jul) $17,064,960 (1,393rd) |
Close (30-Jun) $0.012 |
Volume (30-Jun) 5,851,219 |
Shortsold (10-Feb) 98,846 (0.00%) (597th) |
|
52w High $6.00 |
52w Low $0.80 |
P/E - |
EPS -1.79 |
OSL released this announcement to the ASX on 22 February 2022, 16:36. The announcement is marked as price sensitive, and is 20 page(s) in length and 674.09kb in size.
You can view all announcements from OSL and see how they appear on a price chart on the announcements page.
At the date of this announcement, OSL was 0.681% short sold according to ASIC data. It was ranked the 246th most shorted stock on the ASX. It remains ranked 597th as of the latest reported data (10 February 2025).
| Other Recent Announcements from OSL | |
|---|---|
| Multi-Centre Data on OncoSil in Metastatic Pancreatic Cancer | 30 June 2023, 9:49 |
| Notification of cessation of securities - OSL | 29 June 2023, 17:51 |
| Ethics Committee Approves PANCOSIL Clinical Trial | 5 June 2023, 9:31 |
| Half Yearly Report and Accounts | 22 February 2022, 16:36 |
| OncoSil approved for Innovation Funding (NUB) in Germany | 3 February 2022, 9:32 |
| Quarterly Activities/Appendix 4C Cash Flow Report | 31 January 2022, 8:30 |
| PanCO Clinical Study on OncoSil Published in ESMO Open | 24 December 2021, 9:00 |
You must be logged in to post a reply.
OncoSil Medical 